6th Annual Pharma Packaging and Labeling USA 201426-27 February 2014, Philadelphia, USA
The 6th year of a truly successful and respected Pharma Packaging and Labeling event is rolling back into town with this year expected to be bigger than ever.
With key legislation on the horizon in California and the counterfeiting market now worth millions of dollars as well as sustainability and green packaging in demand, the need for this event is heightened.
We aim to bring you more compelling speakers talking about the subjects that matter to you. Following extensive research into the market we have been able identify key themes to discuss, issues to debate and people you want to meet all under one roof.
This outstanding event will provide a fantastic opportunity for exhibitors to promote their products and services to senior level decision makers from the region. Exhibition spaces are filling up due to the success of last year’s event as well as the global reputation of this world-renowned series.
Pharma Packaging and Labeling 2014 aims to target specific areas of the market in an interesting and insightful manner.
Rondo Pak would like to welcome all attendees of Pharma Packaging and Labeling to their drink reception taking place at the end of day one, on the 26th of February.
Australia's largest virology and communicable disease research centre Burnet Institute has partnered with ARTES Biotechnology to develop a new vaccine to treat malaria.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the full marketing approval of Pharmacyclics' Imbruvica (ibrutinib) in the EU for treatment of two blood cancers.
Clinical stage biopharmaceutical company Clementia Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its palovarotene to treat fibrodysplasia ossificans progressive (FOP).
Gilead Sciences has obtained US Food and Drug Administration (FDA) approval for its Zydelig (idelalisib) 150mg tablets for treatment of three B-cell blood cancers.
Alexion Pharmaceuticals has announced that the European Medicines Agency (EMA) has validated and granted accelerated assessment for its marketing authorisation application for asfotase alfa to treat hypophosphatasia.